TREATMENT OF ALLERGIC SKIN DISEASES
|
|
- Job Malone
- 6 years ago
- Views:
Transcription
1 TREATMENT OF ALLERGIC SKIN DISEASES Prof. Dr.Oktay Taskapan, MD Professor of Dermatology & Allergic Diseases GATA School of Medicine, Haydarpasa Teaching Hospital, Department of Medicine, Section of Allergy, Istanbul, Turkey Allergic skin diseases is considered as an umbrella term which includes three main clinical entities: atopic dermatitis, urticaria/angioedema and allergic contact dermatitis. Cutaneous findings are also seen during the course of adverse drug reactions, insect allergy and food hypersensitivity. However, here we will focus on main dermatoallergic diseases. Atopic Dermatitis(AD): AD is a chronically relapsing inflammatory pruritic skin disease that may be regarded as the dermatologic manifestation of atopic diathesis. It is commonly associated with allergic rhinitis and/or allergic bronchial asthma. There are a number of studies reporting an increasing prevalance of AD. It is an important problem especially in developed countries. AD begins before the age of 5 years in almost 85 % of cases. The patient s age, psycological status, associated respiratory allergies, nature and stages of skin lesions (acute, subacute, chronic) and intensity of AD should be considered and therapeutic management should be individually tailored. That patients education is one of the indispensable parts of therapy must always be kept in mind. AD patients should avoid triggering factors (sweating, food and inhalant alergens, infections etc.) and Page 1
2 irritants (wool and synthetic clothing, soaps and irritating skin care products, hot water etc.). Therapeutic approaches in AD is outlined below: 1.Topical treatment Skin hydration and emollient use: This is the basic therapy for AD patients. Dryness of the skin and dysfunction of the cutaneous barrier system cause transepidermal water loss, and result in inflammation and pruritus. Emollients / moisturizers (creams or ointments) should be applied within 3 minutes after bathing to retain hydration. Topical corticosteroids (TCS): Topical corticosteroids are the mainstay of acute AD flare-up therapy. They may be used in all stages of AD. Topical calcineurin inhibitors (TCI): Pimecrolimus and tacrolimus are anti-inflammatory molecules which are effective in AD with a good safety profile. Transient burning sensation is the most frequently observed side effect. The use of TCI in children younger than 2 years is currently not recommended. Topical antimicrobial agents: Fusidic acid and mupirocin might be used in order to eradicate S.aureus for infected lesions of AD. Since long-term treatment may cause development of resistant strains, topical antibiotics should be applied for only days. 2.Systemic treatment Systemic corticosteroids: Long-term oral therapy should be avoided because of serious side effects. A Short course of systemic corticosteroid therapy may be considered in acute exacerbations. Systemic antibiotics: Systemic antibiotics should be used for generalized bacterial secondary cutaneous infections in AD for about 10 days. Maintenance therapy for prolonged periods may result in colonization of methicillin-resistant S aureus. Page 2
3 Antihistamines: The therapeutic value of antihistamines are very limited in AD. First generation antihistamines may bring some benefit with their sedative effect. Long-term treatment with cetirizine of infants with AD might help to reduce the duration and the amount of TCS used. Cyclosporine A: Cyclosporine A was found to be effective in AD. However its use should be limited to severe, teratment-resistant cases because of possible side effects. Immunosuppressive agents (azathioprine, methotrexate): They may be effective in severe cases. Omalizumab: Anti-IgE may be a reasonable alternative in severe refractory AD cases with high IgE levels. 3.Phototherapy: Acute AD flares may respond to phototherapy. Narrow-band UVB ( nm), UVA ( nm), UVA-1 ( nm), PUVA or bath-puva therapy are the commonly accepted ones. TCS may be combined with these modalities. Phototherapy shouldn t be used in children younger than 12 years. 4.Allergen-specific immunotherapy (IT): IT in AD is controversial. A recent multi-center, randomized trial which investigated the efficacy of house dust mite immunotherapy in cases with AD revealed a dose-dependent improvement and reduced the need for TCS. A stepwise therapeutic management based on the intensity of the disease seems reasonable in AD: Mild AD or only dry skin: Skin hydration, emollients / moisturizers, avoidance of irritants, elimination of triggering factors. Mild to moderate AD: In addition to the general supportive measures outlined above, low-mid potency TCS and / or TCI Page 3
4 Moderate to severe AD: Mid-high potency TCS and/ or TCI Recalcitrant, severe AD: Systemic therapy and phototherapy. Use of probiotics (Lactobacillus GG) in primary prevention of AD is still a matter of debate. Urticaria / Angioedema: While urticaria is characterized by itchy wheals, painful or nonpruritic swelling of the subcutaneous and submucosal tissues are defined as angioedema. It seems reasonable to use urticaria as a wide term of a disease spectrum ranging from localized urticarial wheals to severe angioedema. Recent classification of urticaria according to the EAACI/GA2 LEN/EDF guideline is shown below: 1. Spontaneous urticaria: Acute urticaria, chronic urticaria (CU) 2. Physical urticaria: Cold contact urticaria, delayed pressure urticaria, heat contact urticaria, solar urticaria, dermographic urticaria (symptomatic dermographism), vibratory urticaria/ angioedema 3. Other urticaria disorders: Aquagenic urticaria, cholinergic urticaria, contact urticaria, exercise-induced urticaria/anaphylaxis Even if urticaria / angioedema is usually evaluated under the main title of allergic skin diseases, allergic factors may play causative role in some cases of acute urticaria. The role of food, drug, latex and contact allergens are very limited in chronic urticaria. The lifetime prevalance of acute urticaria is %. In most cases, underlying factors (drug, infections etc.) are recognized, and therapeutic management with oral antihistamines is satisfactory. Page 4
5 However, short-course of oral corticosteroid therapy should always be considered in moderate to severe cases with acute urticaria. Chronic urticaria,defined as the occurrence of wheals for a minimum of 6 weeks, is an extremely disabling condition and it is associated with angioedema in almost 50% of patients. Anti-FcεRI or anti-ige autoantibodies have been detected in a subgroup (30-50%) of chronic idiopathic urticaria (CIU) which is called as chronic autoimmune urticaria (COU). In addition, about one-fifth of CU patients is associated with thyroid autoimmunity. In general, cases of COU are more resistant to therapeutic approaches. CU is triggered by multiple factors including infections /infestations, autoreactivity, non-allergic hypersensitivity (non-steroid antiinflammatory drugs: NSAIDs, food additives) and malignity on the basis of a genetic predisposition. The first and most important step in therapeutic management in all urticaria cases is to obtain a detailed history regarding possible triggering and etiologic factors. Following items should be investigated meticulously: Time of onset Frequency, duration and diurnal variation of wheals Shape, size, colour and distribution of wheals Appearance and colour of lesional areas after resolution of urticarial plaques (hperpigmentation or purpuric changes vasculitis?) Associated angioedema Associated symptoms: Itching, burning, pain Family history of atopy Importance of physical factorsin the appearance of lesions: Cold, heat, mechanical traumas, pressure, vibration, water, ultraviolet light etc. Triggering factors: Food, insect sting, emotion etc. Page 5
6 Use of drugs: Non-steroid anti-inflammatory drugs, hormones, alternative remedies etc. Associated systemic symptoms: Fever, weight loss, fatigue, abdominal pain, lymphadenopathy etc. Associated other diseases, infections and infestations Occupation and hobbies Treatment of CIU is a difficult task which requires close patientphysician collaboration. Avoidance of known eliciting stimuli (drugs, stress, parasites, helicobacter pylori etc.) brings benefit in all cases. However, it is impossible to find any triggering factor or underlying disease in most patients. Cases of COU should be more closely examined and followed. Second-generation H1 receptor antagonists are still the mainstay of therapy. Step-wise algorithmic approach will be reasonable in the treatment of CU : 1. Second generation antihistamines 2. First generation antihistamines or doxepin can be added, or the dose of second generation agents are increased 3. Short-term oral corticosteroid therapy may be added 4. Second generation antihistamines + anti-leukotrienes 5. Thyroxine can be considered if there is evidence of thyroid autoimmunity 6. Cyclosporin A 7. Other therapies: Sulfasalazine, dapsone, colchicine, IVIG, plasmapheresis, methotrexate, warfarin, mycophenolate mofetil, tacrolimus Physical urticaria is not defined as chronic urticaria in the light of the recent classification. Avoidance of physical stimuli is the basic rule in the therapeutic management. However, some cases of physical urticaria (delayed pressure urticaria, cold urticaria etc.) are resistant to standard antihistamine therapy. Page 6
7 The most important and frequently encountered physical urticarias are reviewed below. Dermographic urticaria: Dermographic urticaria or its severe form, symptomatic dermographism(sd) is characterized by an exaggerated response (itching associated with burning) to a minor stroking, rubbing or scratching. It may respond to second generation antihistamines or ketotifen. In resistant cases, the antihistamine dose may be increased. SD is a distressing disease; even light pressure or rubbing from clothes, the movement of collars or cuffs may provoke urticarial reactions. Although it is defined as an idiopathic disease in most textbooks, we documented a close temporal relationship between SD and psychic factors, drug reactions and scabies Delayed pressure urticaria (DPU): Typical lesions of DPU are deep, painful swellings developing 2-6 hours after exposure to a pressure. Carrying a heavy bag by a strap on the shoulder, wearing tight belt or tight shoes may provoke DPU. It is an important occupational problem for manual workers. Almost one-third of patients with CIU has been shown to be associated with DPU. DPU poorly respond to treatment approaches. Second generation antihistamines may be tried, but they are usually ineffective. Anti-leukotrienes may be added to antihistamines. Oral corticosteroids may be effective in high doses, however their long-term use should be avoided because of well-known side effects. Promising results have been obtained with dapsone and sulfasalazine. IVIG and etanercept may be tried in resistant cases. We obtained the best result with sulfasalazine in a DPU patient unresponsive to high dose oral antihistamines, anti-leukotrienes and oral corticosteroids (personal observation) Page 7
8 Acquired cold urticaria (ACU): ACU is defined as immediate urticarial reaction to cold. Systemic symptoms ranging from headache, wheezing and visual disturbance to anaphylactic shock with angioedema may develop in some patients following widespread cold exposure (for example, during aquatic activities). Patients should avoid exposure to cold and abrupt transitions from warm to cold as well. Most patients with ACU respond to high dose antihistamines, up to four times the daily recommended dose. Anti-leukotrienes may be added to antihistamines. In some patients, antibiotic therapy might be considered, even if there is no underlying infection. Systemic corticosteroids, cyclosporin A and anti-ige should be considered in resistant cases. Allergic Contact Dermatitis: Allergic contact dermatitis (ACD), a delayed-type hypersensitivity reaction to allergens, is one of the most common skin diseases with a great socio-economic impact. Elimination of the contact allergen and cross-reacting substances is the basic rule in the treatment of ACD. However, avoidance may not be easy, especially in occupational ACD. Therapeutic agents and methods available for ACD are outlined below : Topical agents: Corticosteroids, antimicrobials, emollients / moisturizers, barrier creams, immunomodulators (TCI: pimecrolimus, tacrolimus) Systemic agents: Corticosteroids, antibiotics, cyclosporin A, azathioprine Phototherapy Topical corticosteroids are the mainstay of therapy in ACD. Basic principles of dermatologic therapy is valid for ACD, AD and all other eczematous lesions: While corticosteroid lotions and creams are Page 8
9 chosen in acute eczematous stage, ointments are used in chronic phase. The potency of topical corticosteroids and localization of lesions (face, trunk, palm etc.) should also be considered. In general, it is reasonable to use high potency corticosteroids initially and switch to less potent ones as the disease improves. Tacrolimus and pimecrolimus have been found to be effective in the treatment of nickel-induced ACD. A multicenter, randomized, vehicle controlled, 3-week study with pimecrolimus cream, twice daily with overnight occlusion was also effective in the treatment for chronic hand dermatitis. Systemic corticosteroids may be used in acute stage of ACD. Their use should be confined to severe, resistant and/or widespread cases. A short course of oral antibiotic therapy is very effective in secondarily infected ACD. Cyclosporin A and azathioprine may be tried in resistant cases. Ultraviolet radiation; PUVA, UVB and bath-puva may bring benefit in generalized ACD, or in cases of unresponsive to standard therapeutic approaches. UV therapy should be individually tailored and be managed by physicians experienced in phototherapy. REFERENCES: 1. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology / American Academy of Allergy, Asthma and Immunology / PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: Beltrani VS, Boguneiwicz M. Atopic dermatitis. DOJ 2003; 9 (2): Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol 1999; 104: S123-S Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002; 13: Page 9
10 5. Lane JE, Cheyney JM, Lane TN et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, doseresponse study. Allergy 2006; 61: Grattan CEH. The urticaria spectrum: recognition of clinical patterns can help management. Clin Exp Dermatol 2004; 29: Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007; 87: Powell RJ, Du Toit GL, Siddique N et al. BSACI guidelines for the management of chronic urticaria and angioedema. Clin Exp Allergy 2007; 37: Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Cur Opin Allergy Clin Immunol 2004; 4: Sheikh J. Advances in the treatment of chronic urticaria. Immunol Allergy Clin N Am 2004; 24 (2): Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006; 45: Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: An open-label prospective study. J Am Acad Dermatol 2005; 52: Taskapan O, Harmanyeri Y. Evaluation of patients with symptomatic dermographism. J Eur Acad Dermatol Venereol 2006; 20: Greaves MW. Urticaria and angioedema. In: Leung DYM, Greaves MW, eds. Allergic Skin Disease. New York & Basel, Marcel Dekker, Inc., 2000: Dawn G, Urcelay M, Ah-Weng A et al. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 2003; 149 (4): Magerl M, Philipp S, Manasterski M et al. Successful treatment of delayed pressure urticaria with anti-tnf-α. J Allergy Clin Immunol 2007; 119: Page 10
11 19. Siebenhaar F, Weller K, Mlynek A et al. Acquired cold urticaria: clinical Picture and update on diagnosis and treatment. Clin Exp Dermatol 2007; 32: Saint-Mezard P, Rosieres A, Krasteva M et al. Allergic contact dermatitis. Eur J Dermatol 2004; 14: Braun-Falco O, Plewig G, Wolf HH, Burgdorf WHC. Dermatology. 2nd edition. Berlin, Springer, 2000; Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatologic Therapy 2004; 17: Belsito DV, Fowler FJ, Marks JG et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73 (1): Page 11
Urticaria is a common, heterogeneous group of disorders
SYMPOSIUM REPORT SUPPLEMENT A Summary of the New International EAACI/GA 2 LEN/EDF/ WAO Guidelines in Torsten Zuberbier, MD Abstract: is a heterogeneous group of disorders, especially acute and angiooedema
More informationThey re Scratching and You re Scratching Your Head: An Approach to the Diagnosis and Management of Acute and Chronic Urticaria
They re Scratching and You re Scratching Your Head: An Approach to the Diagnosis and Management of Acute and Chronic Urticaria Adelle R. Atkinson, MD, FRCPC Sea Courses May/June 2017 Copyright 2017 by
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationWhat to do when patch testing is negative?
What to do when patch testing is negative? Christen M. Mowad MD Clinical Professor of Dermatology Geisinger Medical Center Danville, PA 17821 cmowad@geisinger.edu I have no disclosures. What to do when
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012
Drug, Treatment, Device name Omalizumab (Xolair; Novartis) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Licensed indication Omalizumab
More information3302: Therapy Options for Patients with Anti-Histamine Resistant Chronic Urticaria
3302: Therapy Options for Patients with Anti-Histamine Resistant Chronic Urticaria Javed Sheikh, M.D. FAAAI Department of Allergy & Clinical Immunology Kaiser Permanente Los Angeles Medical Center Disclosure
More informationManaging urticaria in primary care
Managing urticaria in primary care Tidman MJ. Managing urticaria in primary care. Practitioner 2015;259(1779)25-28 Dr Michael J. Tidman MD FRCP (Ed) FRCP (Lond) Consultant Dermatologist, Department of
More informationManagement of Chronic Idiopathic Urticaria
9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationBiologic Therapies for Atopic Dermatitis and Beyond
Biologic Therapies for Atopic Dermatitis and Beyond Jonathan Corren, M.D. Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA Disclosures Genentech - research Medimmune/AZ -
More informationFIT Board Review Corner April 2017
FIT Board Review Corner April 2017 Welcome to the FIT Board Review Corner, prepared by Tammy Peng, MD, and Amar Dixit, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More informationUsefulness of the Autologous Serum Test for the Diagnosis of Chronic Idiopathic Urticaria
ÖM Çelen, et al Ann Dermatol Vol. 26, No. 5, 2014 http://dx.doi.org/10.5021/ad.2014.26.5.592 ORIGINAL ARTICLE Usefulness of the Autologous Serum Test for the Diagnosis of Chronic Idiopathic Urticaria Öykü
More informationCHRONIC URTICARIA; IT S MORE THAN JUST ANTIHISTAMINES!
CHRONIC URTICARIA; IT S MORE THAN JUST ANTIHISTAMINES! Randy D. Danielsen, PhD, PA, DFAAPA Dean & Professor Arizona School of Health Sciences A.T. Still University Ûr tĭ-kâr ē-ә Urticaria is characterized
More informationUrticaria and Angioedema. Allergy and Immunology Awareness Program
Urticaria and Angioedema Allergy and Immunology Awareness Program 1 Urticaria and Angioedema Allergy and Immunology Awareness Program Urticaria Commonly known as hives, urticarial is an itchy rash with
More informationDo My Patient s Hives Always = Allergy? Julie Sterbank, DO Allergy & Immunology MetroHealth Medical Center
Do My Patient s Hives Always = Allergy? Julie Sterbank, DO Allergy & Immunology MetroHealth Medical Center I do not have any financial or conflicts of interest to make regarding any of the items or conditions
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAutologous Serum Skin Test in Chronic Idiopathic Urticaria: Prevalence, Correlation and Clinical Implications
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2006) 24: 201-206 Autologous Serum Skin Test in Chronic Idiopathic Urticaria: Prevalence, Correlation and Clinical Implications Kanokvalai Kulthanan, Sukhum
More informationIMMUNODEFICIENCIES PRIMARY ALLERGIES PRIMARY IMMUNODEFICIENCIES AND ALLERGIES
PRIMARY IMMUNODEFICIENCIES ALLERGIES PRIMARY IMMUNODEFICIENCIES AND ALLERGIES 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS IgE CID Immunoglobulin E Combined Immunodeficiency IL5 Interleukin 5 IPOPI PID
More information2012/12/5. Principle of the management of urticaria. The efficacy of systemic steroid on urticaria depends of subtypes urticaria
6 December 2012: 13:3015:00 G.04 (HICC) The Hyderabad International Convention Centre (HICC) in Hyderabad, India WISC 2012; WAO International Scientific Conference Postgraduate Course 16: URTICARIA & ANGIOEDEMA
More informationUrticaria. Appearance. Epidemiology [1] Aetiology [2]
Page 1 of 5 View this article online at: patient.info/doctor/urticaria-pro Urticaria Urticaria, otherwise known as hives, is an itchy red blotchy rash resulting from swelling of the superficial part of
More informationContact Dermatitis In Atopic Patients
Contact Dermatitis In Atopic Patients Jenny Murase, MD Palo Alto Foundation Medical Group Director of Patch Testing University of California, San Francisco Associate Clinical Professor Disclosures Consultant
More informationA Case Series Study of Eighty-Five Chronic Spontaneous Urticaria Patients Referred to a Tertiary Care Center
Treatment of Urticaria Ann Dermatol Vol. 26, No. 1, 2014 http://dx.doi.org/10.5021/ad.2014.26.1.73 ORIGINAL ARTICLE A Case Series Study of Eighty-Five Chronic Spontaneous Urticaria Patients Referred to
More informationProfessor Rohan Ameratunga Clinical Immunologist and Allergist Auckland
Professor Rohan Ameratunga Clinical Immunologist and Allergist Auckland 16:30-17:25 WS #170: Eczema Management 17:35-18:30 WS #182: Eczema Management (Repeated) Managing ECZEMA A/Prof Rohan Ameratunga
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationConstitutional eczema
Patient information Constitutional eczema What is constitutional eczema? Constitutional eczema, also called atopic eczema, is a form of eczema that mainly occurs in childhood. Eczema usually starts before
More informationDepartment of Paediatrics Clinical Guideline URTICARIA GUIDELINE BACKGROUND
Department of Paediatrics Clinical Guideline URTICARIA GUIDELINE BACKGROUND This guideline is intended for use in A&E and general paediatric OPD to assist with the management of initial presentations of
More informationomalizumab 150mg solution for injection (Xolair ) SMC No. (1017/14) Novartis Pharmaceuticals UK Ltd
omalizumab 150mg solution for injection (Xolair ) SMC No. (1017/14) Novartis Pharmaceuticals UK Ltd 05 December 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPerspectives in Primary Care: Evaluating and Managing Patients With Chronic Urticaria
Perspectives in Primary Care: Evaluating and Managing Patients With Chronic Urticaria Please complete the preassessment located in your meeting handout before the program begins. Sponsorship and Support
More informationItchy, Scratchy, Red and Patchy: Derm tips for primary care. Robert Gniadecki, MD
Itchy, Scratchy, Red and Patchy: Derm tips for primary care Robert Gniadecki, MD Faculty/Presenter Disclosure Faculty: Robert Gniadecki Relationships with financial sponsors: Grants/Research Support: N/A
More informationAbstract ORIGINAL ARTICLE. B Engin,* M Özdemir
JEADV ISSN 1468-3083 Blackwell Publishing Ltd ORIGINAL ARTICLE Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic
More informationThe management of chronic urticaria in primary care for adults and children
The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this
More informationDisease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria
ORIGINAL ARTICLE Korean J Intern Med 2018;33:185-192 https://doi.org/10.3904/kjim.2015.195 Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria Won-Sun
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationDOES URTICARIA RULE YOUR LIFE?
DOES URTICARIA RULE YOUR LIFE? Helpline 01322 619898 www.allergyuk.org The content of this leaflet was written and developed by Allergy UK. This leaflet is kindly supported by an unrestricted grant from
More informationXolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below
More information4/12/18. Refractory Chronic Urticaria: When Omalizumab Fails. Objectives. Disclosures
Refractory Chronic Urticaria: When Omalizumab Fails David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures n Research Grants n NIH n Honoraria n UpToDate,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationComparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis
Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Cream 1% DK/H/PSUR/0009/005 Date of FAR:
0BCore Safety Profile Active substance: Pimecrolimus Pharmaceutical form(s)/strength: Cream 1% P-RMS: DK/H/PSUR/0009/005 Date of FAR: 06.06.2013 4.3 Contraindications Hypersensitivity to pimecrolimus,
More informationThe Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah
The Itch That Rashes Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah 1 Conflict of Interest No conflict of interest Will discuss off label use of medications 2 3 Most likely diagnosis?
More informationNew Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003
New Medicine Report Document Status Pimecrolimus Reviewed by Suffolk D&T RED- Hospital only Date of Last Revision 6 th March 2003 Approved Name Pimecrolimus Trade Name Elidel Manufacturer Novartis Legal
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS. Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine
ATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine THE PLAN Is it atopic dermatitis? What is atopic dermatitis? Guidelines
More informationCutaneous Immediate-Type Reactions to Textiles
Elsner P, Hatch K, Wigger-Alberti W (eds): Textiles and the Skin. Curr Probl Dermatol. Basel, Karger, 2003, vol 31, pp 166 170 Cutaneous Immediate-Type Reactions to Textiles Andreas J. Bircher Allergy
More informationATOPIC ECZEMA. What are the aims of this leaflet?
ATOPIC ECZEMA What are the aims of this leaflet? This leaflet has been written to help you understand more about atopic eczema. It tells you what it is, what causes it, what can be done about it, and where
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More informationHow to Successfully Manage Chronic Urticaria? & Tall Tales from Texas
How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures Honoraria/Speakers Bureau
More informationAllergy Medications. Antihistamines. are very safe. Although usually taken as tablets, they may be prescribed as a liquid or syrup for young children
The treatments prescribed for allergy control the symptoms and reactions; they do not cure the condition. However, using treatments as prescribed can show a huge change in a patient s health, mood and
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationMast Cell Mediators. Updates on Chronic Urticaria 11/1/2016. Urticaria: What happens in the skin?
Urticaria: What happens in the skin? Updates on Chronic Urticaria Kent Woo, MD (USA) Allergy/Immunology Internal Medicine C A U S E MC, mast cell IgE Fc eri MC Release of Mediators Activation Vasodilation
More informationTreatment Options for Refractory Urticaria
Treatment Options for Refractory Urticaria David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology University of Texas Southwestern Medical Center
More informationCOMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio
COMMON SKIN CONDITIONS IN PRIMARY CARE Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio DISCLOSURE The Speaker and members of the planning committee do not have a conflict of interest
More informationAutologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report
Brief Communication Allergy Asthma Immunol Res. 2014 January;6(1):89-94. http://dx.doi.org/10.4168/aair.2014.6.1.89 pissn 2092-7355 eissn 2092-7363 Autologous Immunoglobulin Therapy in Patients With Severe
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationLearning Objectives 10/26/2017. New Treatments in Atopic Dermatitis
New Treatments in Atopic Dermatitis Lynda C. Schneider, MD Professor of Pediatrics, Harvard Medical School Boston Children s Hospital lynda.schneider@childrens.harvard.edu Disclosures: Lynda Schneider,
More informationREFERRAL GUIDELINES - SUMMARY
Clinical Immunology & Allergy Unit LEEDS TEACHING HOSPITALS NHS TRUST REFERRAL GUIDELINES - SUMMARY THESE GUIDELINES ARE DESIGNED TO ENSURE THAT PATIENTS REQUIRING SECONDARY CARE ARE SEEN EFFICIENTLY AND
More informationTreating dermatomyositis
Treating dermatomyositis David Fiorentino, MD, PhD Stanford University School of Medicine Department of Dermatology Department of Medicine (Rheumatology) September 25, 2010 DM affects many organs Approaching
More informationHypersensitivity diseases
Hypersensitivity diseases Downloaded from: StudentConsult (on 18 July 2006 11:40 AM) 2005 Elsevier Type-I Hypersensitivity Basic terms Type-I = Early= IgE-mediated = Atopic = Anaphylactic type of hypersensitivity
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationEczema. By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University
Eczema By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University Dermatitis= Eczema =Spongiosis Eczema Atopic Seborrheic Contact Allergic Irritant Nummular Asteatotic Stasis Neurodermatitis/Lichen Simplex
More informationEczema & Dermatitis Clinical features: Histopathological features: Classification:
Eczema & Dermatitis Eczema is an inflammatory reactive pattern of skin to many and different stimuli characterized by itching, redness, scaling and clustered papulovesicles. Eczema and dermatitis are synonymous
More informationEAACI/GA 2 LEN/EDF guideline: definition, classification and diagnosis of urticaria
Allergy 2006: 61: 316 320 Copyright Ó Blackwell Munksgaard 2005 Review article ALLERGY DOI: 10.1111/j.1398-9995.2005.00964.x EAACI/GA 2 LEN/EDF guideline: definition, classification and diagnosis of This
More informationTRIGGERS & TREATMENT OF ATOPIC DERMATITIS COA#PCIA0809 CE Activity provided by PCI Journal
TRIGGERS & TREATMENT OF ATOPIC DERMATITIS COA#PCIA0809 CE Activity provided by PCI Journal INSTRUCTIONS 1. Read the article. 2. Take the test, record your answers in the test answer section (Section B)
More informationAtopic Dermatitis. Atopic dermatitis (AD) is very common with a. Going Skin Deep With. Carl s rashes
Focus on CME at Dalhousie University Going Skin Deep With Atopic Dermatitis Scott Murray, MD, FRCP(C), BSc Atopic dermatitis (AD) is very common with a tendency for itching and inflammation of the skin.
More informationManaging and Minimizing Flare-ups in Atopic Dermatitis
Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology
More informationO R I G I N A L A R T I C L E Eur Ann Allergy Clin Immunol Vol 49, N 5, , 2017
O R I G I N A L A R T I C L E Eur Ann Allergy Clin Immunol Vol 49, N 5, 22-224, 217 T. Boonpiyathad, A. Sangasapaviliya Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous
More informationImmunologic Mechanisms of Tissue Damage. (Immuopathology)
Immunologic Mechanisms of Tissue Damage (Immuopathology) Immunopathology Exaggerated immune response may lead to different forms of tissue damage 1) An overactive immune response: produce more damage than
More information5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema. Part 1. Keys to Adherence: Simplify regimen & Educate
5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema Luz Fonacier, MD Professor of Clinical Medicine State University of New York at Stony Brook Head of Allergy & Training Program Director
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Urticaria These podcasts are designed to give medical students an overview of key topics in pediatrics. The audio versions
More informationPsoriasis: Causes, Symptoms, And Treatment
Psoriasis: Causes, Symptoms, And Treatment We all know that a healthy immune system is good. But, do you know that an overactive immune system can cause certain conditions like Psoriasis? Read on to find
More informationTreatment of Severe Atopic Dermatitis with a Combination of Subcutaneous Allergen Immunotherapy and Cyclosporin
Original Article http://dx.doi.org/10.3349/ymj.2012.53.1.158 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(1):158-163, 2012 Treatment of Severe Atopic Dermatitis with a Combination of Subcutaneous
More informationAllergy overview. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
Allergy overview Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Adaptive Immune Responses Adaptive immune responses allow responses against
More informationThe Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis John Oppenheimer MD Div Allergy and Immunology UMDNJ-Rutgers Potential Conflicts of Interest Consultant GSK, Teva,
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More informationDrug allergy and Skin Disorders. Timothy Craig, DO, FACOI Professor of Medicine and Pediatrics Distinguished Educator Penn State University, Hershey
Drug allergy and Skin Disorders Timothy Craig, DO, FACOI Professor of Medicine and Pediatrics Distinguished Educator Penn State University, Hershey The best screening test for anaphylaxis is? A. histamine
More informationAnti-IgE: beyond asthma
Anti-IgE: beyond asthma Yehia El-Gamal, MD, PhD, FAAAAI Professor of Pediatrics Pediatric Allergy and Immunology Unit Children s Hospital, Ain Shams University Member, WAO Board of Directors Disclosure
More informationIdiopathic Anaphylaxis. Paul A. Greenberger, MD, FAAAAI 2/28/2014 Course # 1605
Idiopathic Anaphylaxis Paul A. Greenberger, MD, FAAAAI 2/28/2014 Course # 1605 Objectives Review definition and classification of idiopathic anaphylaxis Consider the differential diagnosis Critique lab
More informationRELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN
RELEVANT DISCLOSURES MANAGING ECZEMA IN INFANTS AND CHILDREN Advisory board member - MEDA (Elidel), Speaking honoraria Bayer (Advantan) Advisory board, consultant, speaker: Pfizer, Abbvie, Janssen, Elli
More informationPerspectives in Primary Care: Evaluating and Managing Patients with Chronic Urticaria
Saturday General Session Perspectives in Primary Care: Evaluating and Managing Patients with Chronic Urticaria Anne Marie Ditto, MD Associate Professor of Medicine Division of Allergy Immunology Northwestern
More informationWhat you need to know about ECZEMA
What you need to know about ECZEMA The Irish Skin Foundation is a national charity with a mission to improve quality of life for people with skin conditions, promote skin health and the prevention of skin
More informationxx Xolair 150 MG SOLR (GENENTECH)
Omalizumab NDC CODE(S) 50242-0040-xx Xolair 150 MG SOLR (GENENTECH) DESCRIPTION Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody which selectively binds to immunoglobulin E (IgE).
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationWhat you need to know about ECZEMA
What you need to know about ECZEMA The Irish Skin Foundation is a national charity with a mission to improve quality of life for people with skin conditions, promote skin health and the prevention of skin
More informationTCIs are only available on prescription and are usually started by a dermatology specialist.
(TCIs) What are topical calcineurin inhibitors? Topical calcineurin inhibitors are treatments that alter the immune system and have been developed for controlling eczema. There are two types available:
More informationNovel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript
Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript Title Slide Welcome to the CME-certified program: Novel Insights in Atopic Dermatitis; Pathways,
More informationUpdate on emollients
Update on emollients Amal Mhanna, MD Pediatric Dermatologist Clemenceau Medical Center Disclosure: I was a member of an advisory board y for J&J and received honoraria. Emollients and moisturizers are
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationIs it allergy? Debbie Shipley
Is it allergy? Debbie Shipley Topics Food Allergy and Eczema Hand Eczema and Patch Testing Urticaria Tackling Allergy Gell and Coombs classification Skin conditions with possible allergic component Allergy
More informationOmalizumab: what benefits should we expect?
ejd150659 INVESTIGATIVE REPORT Omalizumab: what benefits should we expect? Ana GIMÉNEZ-ARNAU 1 Manel VELASCO 2 Jose Carlos ARMARIO HITA 3 Moises LABRADOR-HORRILLO 4 Juan Francisco SILVESTRE SALVADOR 5
More informationSubtypes of chronic Urticaria in patients attending allergy clinics in Venezuela
O R I G I N A L A R T I C L E S Eur Ann Allergy Clin Immunol Vol 46, N 6, 210-215, 2014 M. Sánchez-Borges 1,2, F. Caballero-Fonseca 2, A. Capriles-Hulett 2 Subtypes of chronic Urticaria in patients attending
More informationPsoriasis. What is Psoriasis? What causes psoriasis? Medical Topics Psoriasis
1 Psoriasis What is Psoriasis? Psoriasis is a long standing inflammatory non-contagious skin disease which waxes and wanes with triggering factors. There is a genetic predisposition in psoriasis. Internationally,
More informationUrticaria. An Evidence-Based Approach to Diagnosis & Management. July 16, 2015 Walter E. Washington Convention Center. Educational partner RMEI, LLC
Urticaria An Evidence-Based Approach to Diagnosis & Management July 16, 2015 Walter E. Washington Convention Center Educational partner RMEI, LLC Session 8: Urticaria: An Evidence-Based Approach to Diagnosis
More informationIMMUNOLOGY. Referral Guidelines NATIONAL REFERRAL GUIDELINES : IMMUNOLOGY. As above Specialist assessment is essential.
PAGE 1 IMMUNOLOGY National PRIMARY IMMUNODEFICIENCY Primary immunodeficiency should be suspected in any patient with recurrent or persistent infection or unusual infection. Recurrent sinopulmonary infections
More informationPredicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers
Predicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers Authors: *Misbah Noshela Ghazanfar, 1 Simon Francis Thomsen 1,2 1. Department of Dermatology, Bispebjerg Hospital, Copenhagen,
More informationItch and Swelling update: Practical Approach to Urticaria & Angioedema
Itch and Swelling update: Practical Approach to Urticaria & Angioedema Robert W Hostoffer, DO, LhD, FAAP, FACOP, FACOI, FCCP Program Director, Allergy/Immunology Fellowship Neha Sanan, DO Allergy & Immunology
More informationLearning Circle: Jan 26, 2011 Childhood Eczema
Learning Circle: Jan 26, 2011 Childhood Eczema Wingfield Rehmus, MD MPH BC Children s Hospital Clinical Assistant Professor, UBC Department of Paediatrics Associate Member, UBC Department of Dermatology
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More information